Influenza vaccine - BiondVax

Drug Profile

Influenza vaccine - BiondVax

Alternative Names: BVX-M001; M 001; Multimeric Multi-Epitope Polypeptide Influenza Vaccine; Multimeric-001 Universal Flu Vaccine; Universal Flu Vaccine

Latest Information Update: 24 Jul 2017

Price : $50

At a glance

  • Originator Weizmann Institute of Science
  • Developer BiondVax Pharmaceuticals; National Institutes of Health
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 21 Jul 2017 Efficacy data from a phase IIb trial in Healthy volunteers released by BiondVax Pharmaceuticals
  • 21 Jun 2017 BiondVax receives notice on its patent application on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines being allowed in Canada
  • 19 Jun 2017 BiondVax Pharmaceuticals secures loan €20 million from European Investment Bank to finance development of M 001 for Influenza virus infections (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top